The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

Inclusion Criteria

• •Female patients aged ≥ 18 years.
• •Histologically confirmed HER2-positive breast cancer (IHC 3+ or IHC 2+ with ISH+).
• •Patients expected to receive pyrotinib-containing regimens for neoadjuvant therapy or metastatic/unresectable breast cancer.
• •·≤1 prior line of anti-HER2 therapy during the recurrent/metastatic stage.
• •Ability to operate a mobile phone and read independently.
• •Deemed psychologically and physically suitable for participation by the investigator.